Anna K. P.
- Country
- Poland
- Department
- Centralny Szpital Kliniczny, Klinika Neurologii
Research Overview
- Phase 2a Study to Evaluate the Safety and Efficacy of Empasiprubart as Add-on Therapy to Efgartigimod in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
- Phase 3 Study of Delpacibart Zotadirsen in Duchenne Muscular Dystrophy with Mutations Amenable to Exon 44 Skipping
- Phase 2a Randomized Double‑Blind Placebo‑Controlled Study of Empasiprubart IV Monotherapy in AChR‑Ab Seropositive Generalized Myasthenia Gravis
Data & Insights
Has run more than one trial at 124 of 255 partner sites.
Specializations
Neuromuscular Disorders
This investigator specializes in treating Duchenne Muscular Dystrophy (DMD), focusing on innovative therapeutic approaches to address bone mineral density complications in pediatric and adolescent patients.
- Pediatric neuromuscular conditions
- Bone health in DMD patients
- Advanced imaging diagnostics
Their research extends to evaluating therapeutic interventions for maintaining musculoskeletal health in young patients with progressive muscular disorders.
Neuroimmunology
The investigator conducts research in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), exploring novel therapeutic approaches for this rare neurological condition.
- Autoimmune neurological disorders
- MOGAD treatment development
- Relapse prevention strategies
Their work encompasses evaluation of targeted therapies for autoimmune conditions affecting the central nervous system.
Therapeutic Innovation
The investigator focuses on evaluating novel biological therapies for rare neurological and neuromuscular conditions, with particular attention to safety and efficacy assessment.
- Biological therapy development
- Clinical efficacy evaluation
- Treatment response monitoring
Their expertise includes comprehensive assessment of therapeutic interventions in both pediatric and adult populations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.